Periostin as a marker of eosinophilic inflammation in patients with asthma and chronic obstructive pulmonary disease

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

BACKGROUND: Asthma and chronic obstructive pulmonary disease are common chronic respiratory diseases. Given their heterogeneity, the study of periostin is a relevant area for establishing the endotypes of airway inflammation and determining further therapy tactics.

AIM: To evaluate periostin levels and determine its significance as a marker of eosinophilic inflammation in patients with asthma and chronic obstructive pulmonary disease.

MATERIALS AND METHODS: The study included 59 patients with asthma and 33 patients with chronic obstructive pulmonary disease. The control group consisted of 37 apparently healthy people, comparable in age and sex, without allergic and bronchial obstructive diseases in anamnesis. The anamnesis data, the number of peripheral blood eosinophils and induced sputum, indices of external respiratory function were evaluated. Levels of specific immunoglobulin E to allergens, periostin level were determined in blood serum by immunoenzyme method. The obtained data were processed using STATISTICA 13 and SPSS Statistic 27 software systems.

RESULTS: The maximum serum periostin concentration 22.5 (17–38) ng/ml was recorded in the patients with asthma, which was significantly higher than in the chronic obstructive pulmonary disease group [16 (12–21) ng/ml; p = 0.006] and control group [20.1 (14.6–24.8) ng/ml; p = 0.044]. The level of periostin in induced sputum in the patients with asthma was significantly higher than in the chronic obstructive pulmonary disease group — 0.05 (0.03–0.6) ng/ml vs 0.03 (0.02–0.04) ng/ml (p = 0.008). The study revealed the correlation between serum periostin level and eosinophil level (r = 0.406; p < 0.05) and with forced expiratory volume in the first second after bronchodilator test (r = 0.366; p < 0.05) as well as with forced expiratory volume in the first second divided by forced vital capacity after bronchodilator test (r = 0.572; p < 0.05).

CONCLUSIONS: Periostin is a promising marker of eosinophilic inflammation in patients with asthma, which can be considered as an indicator of fixed bronchial obstruction and a molecule linking T2-inflammation and airway remodelling. In a group of chronic obstructive pulmonary disease patients, the use of periostin for diagnostic and prognostic purposes requires further investigation and larger studies.

全文:

受限制的访问

作者简介

Valeriy Kuznetsov

North-Western State Medical University named after I.I. Mechnikov

编辑信件的主要联系方式.
Email: valeriy_smith@inbox.ru
ORCID iD: 0000-0001-9439-4749
SPIN 代码: 7432-9779

postgraduate student

俄罗斯联邦, Saint Petersburg

Yana Kozlova

North-Western State Medical University named after I.I. Mechnikov

Email: kozlova510@mail.ru
ORCID iD: 0000-0002-4602-2438
SPIN 代码: 5842-6039

MD, Dr. Sci. (Med.), Assistant Professor

俄罗斯联邦, Saint Petersburg

Ekaterina Frolova

North-Western State Medical University named after I.I. Mechnikov

Email: ekaterina.frolova@szgmu.ru
ORCID iD: 0000-0002-7696-2236
SPIN 代码: 9904-8776

MD, Cand. Sci. (Med.)

俄罗斯联邦, Saint Petersburg

Aleksandra Uchevatkina

North-Western State Medical University named after I.I. Mechnikov

Email: a.uchevatkina@szgmu.ru
ORCID iD: 0000-0001-6688-7781
SPIN 代码: 3001-4022

MD, Cand. Sci. (Med.)

俄罗斯联邦, Saint Petersburg

Larisa Filippova

North-Western State Medical University named after I.I. Mechnikov

Email: larisa.filippova@szgmu.ru
ORCID iD: 0000-0003-4167-7440
SPIN 代码: 6810-0871

MD, Cand. Sci. (Med.)

俄罗斯联邦, Saint Petersburg

Oleg Aak

North-Western State Medical University named after I.I. Mechnikov

Email: oleg.aak@szgmu.ru
ORCID iD: 0000-0001-8130-7503
SPIN 代码: 1198-7810

Cand. Sci. (Chem.)

俄罗斯联邦, Saint Petersburg

Natalya Vasilieva

North-Western State Medical University named after I.I. Mechnikov

Email: mycobiota@szgmu.ru
ORCID iD: 0000-0003-3693-5468
SPIN 代码: 3829-4370

MD, Dr. Sci. (Med.), Professor, Honored Scientist of the Russian Federation

俄罗斯联邦, Saint Petersburg

参考

  1. Avdeev SN, Emelyanov AV, Aisanov ZR, et al. Problems and opportunities to improve diagnosis of asthma and chronic obstructive pulmonary disease in Russia: resolution of advisory board. Terapevticheskii Arkhiv. 2022;94(4):524–529. EDN: ZSVKEK doi: 10.26442/00403660.2022.04.201487
  2. Bystritskaya EV, Bilichenko TN. The morbidity, disability, and mortality associated with respiratory diseases in the Russian Federation (2015–2019). Pulmonologiya. 2021;31(5):551–561. EDN: KXDQEV doi: 10.18093/0869-0189-2021-31-5-551-561
  3. Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015;5(2):020415. doi: 10.7189/jogh.05-020415
  4. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–171. doi: 10.1016/S0140-6736(14)61682-2
  5. Lopez A, Shibuya K, Rao C, et al. Obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27(2):397–412. doi: 10.1183/09031936.06.00025805
  6. WHO. Projections of mortality and causes of death, 2015 and 2030 [Internet]. Available from: https://bigdataanalyticsnews.com/projections-of-mortality-and-causes-of-death-2015-and-2030/. Accessed: 11 Jan 2022.
  7. Avdeev SN, Nenasheva NM, Zhudenkov KV, et al. Prevalence, morbidity, phenotypes and other characteristics of severe bronchial asthma in Russian Federation. Pulmonologiya. 2018;28(3):341–358. EDN: XWCRRZ doi: 10.18093/0869-0189-2018-28-3-341-358
  8. Clinical recommendations “Bronchial asthma” 2021 [Internet]. Available from: https://cr.minzdrav.gov.ru/recomend/359_2. Accessed: 4 Feb 2022. (In Russ.)
  9. Ono J, Takai M, Kamei A, et al. Pathological roles and clinical usefulness of periostin in type 2 inflammation and pulmonary fibrosis. Biomolecules. 2021;11(8):1084. doi: 10.3390/biom11081084
  10. Okamoto M, Izuhara K, Ohta S, et al. Ability of periostin as a new biomarker of idiopathic pulmonary fibrosis. Adv Exp Med Bio. 2019;1132:79–87. doi: 10.1007/978-981-13-6657-4_9
  11. Yoshihara T, Nanri Y, Nunomura S, et al. Periostin plays a critical role in the cell cycle in lung fibroblasts. Respir Res. 2020;21(1):38–50. doi: 10.1186/s12931-020-1299-0
  12. Bhatt S, Agusti A, Bafadhel M, et al. Phenotypes, etiotypes, and endotypes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2023;208(10):1026–1041. doi: 10.1164/rccm.202209-1748SO.
  13. The Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2023 [Internet]. Available from: https://www.kineed.org/wp-content/uploads/2023/06/GINA-2023-Full-Report-2023-WMS.pdf. Accessed: 19 May 2023.
  14. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 [Internet]. Available from: https://goldcopd.org/2023-gold-report-2/ Accessed: 16 Sep 2023.
  15. Clinical recommendations “Chronic obstructive lung disease” 2021 [Internet]. Available from: https://cr.minzdrav.gov.ru/recomend/603_2. Accessed: 23 June 2022. (In Russ.)
  16. Masalskiy SS, Kalmykova АS, Ukhanova ОP. Comprehensive assessment of serum periostin – a new marker for uncontrolled asthma in children Russian Journal of Allergy. 2018;15(1):55–57. EDN: YNKNGX
  17. Izuhara K, Nunomura S, Nanri Y, et al. Periostin in inflammation and allergy. Cell Mol Life Sci. 2017;74(23):4293–4303. doi: 10.1007/s00018-017-2648-0
  18. Takayama G, Arima K, Kanaji T, et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol. 2006;118(1):98–104. doi: 10.1016/j.jaci.2006.02.046
  19. Shakhova NV. Periostin as a biomarker of bronchial asthma. Current Pediatrics. 2019;18(5):339–345. EDN: ZIXBFC doi: 10.15690/vsp.v18i5.2056
  20. Ono J, Takai M, Kamei A, et al. Periostin forms a functional complex with IgA in human serum. Allergol Int. 2020;69(1):111–120. doi: 10.1016/j.alit.2019.05.014
  21. Scheerens H, Arron JR, Zheng Y, et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin Exp Allergy. 2014;4(1):38–46. doi: 10.1111/cea.12220
  22. Naik PK, Bozyk PD, Bentley JK, et al. Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2012;303(12):1046–1056. doi: 10.1152/ajplung.00139.2012
  23. Jia G, Erickson RW, Choy DF, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012;130(3):647–654.e10. doi: 10.1016/j.jaci.2012.06.025
  24. Kato G, Takahashi K, Izuhara K, et al. Markers that can reflect asthmatic activity before and after reduction of inhaled corticosteroids: a pilot study. Biomark Insights. 2013;8:97–105. doi: 10.4137/BMI.S12537
  25. Casale TB. Biologics and biomarkers for asthma, urticaria, and nasal polyposis. J Allergy Clin Immunol. 2017;139(5):1411–1421. doi: 10.1016/j.jaci.2017.03.006
  26. Akar-Ghibril N, Casale T, Custovic A, et al. Allergic endotypes and phenotypes of asthma. J Allergy Clin Immunol Pract. 2020;8(2):429–440. doi: 10.1016/j.jaip.2019.11.008
  27. Izuhara K, Nunomura S, Nanri Y, et al. Periostin: An emerging biomarker for allergic diseases. Allergy. 2019;74(11):2116–2128. doi: 10.1111/all.13814
  28. Wu G, Meng X, Zheng P, et al. Elevated serum levels of periostin in patients with allergic bronchopulmonary aspergillosis. Mycoses. 2019;62(9):780–789. doi: 10.1111/myc.12957
  29. Kozlova Y, Frolova E, Uchevatkina A, et al. Diagnostic markers of allergic bronchopulmonary aspergillosis in patients with severe asthma. Mycoses. 2020;63(6):596–603. doi: 10.1111/myc.13083
  30. Nejman-Gryz P, Górska K, Krenke K, et al. Periostin concentration in exhaled breath condensate in children with mild asthma. J Asthma. 2021;58(1):60–68. doi: 10.1080/02770903.2019.1659312
  31. O’Connell P, Gaston B, Bonfield T, et al. Periostin levels in children without respiratory disease. Pediatr Pulmonol. 2019;54(2):200–204. doi: 10.1002/ppul.24206
  32. Baranov DZ, Trofimov VI, Lapin SV, et al. Evaluation of periostin in case of bronchoostructive diseases. Therapy. 2021;7(8)(50):22–29. EDN: QEOLUD doi: 10.18565/therapy.2021.8.22-29
  33. Masalskiy SS, Kalmykova AS, Ukhanova OP, et al. Use serum periostin as marker of worsening pediatric allergic asthma. Allergology and Immunology in Paediatrics. 2018;4(55):37–48. EDN: YZXRAD doi: 10.24411/2500-1175-2018-00021
  34. Scichilone N, Crimi C, Benfante A, et al. Higher serum levels of periostin and the risk of exacerbations in moderate asthmatics. Asthma Res Pract. 2016;2(1):1. doi: 10.1186/s40733-015-0019-x
  35. Shirai T, Hirai K, Gon Y, et al. Combined assessment of serum periostin and YKL-40 May identify asthma-COPD overlap. J Allergy Clin Immunol Pract. 2019;7(1):134–145.e1. doi: 10.1016/j.jaip.2018.06.015
  36. Liu Y, Zhang S, Chen R, et al. Meta-analysis of randomized controlled trials for the efficacy and safety of anti-interleukin-13 therapy with lebrikizumab in patients with uncontrolled asthma. Allergy Asthma Proc. 2018;39(5):332–337. doi: 10.2500/aap.2018.39.4149
  37. Gottlow M, Svensson DJ, Lipkovich I, et al. Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma. BMC Pulm Med. 2019;19(1):129. doi: 10.1186/s12890-019-0889-4
  38. Abramson MJ, Schattner RL, Sulaiman ND, et al. Accuracy of asthma and COPD diagnosis in Australian general practice: a mixed methods study. Prim Care Respir J. 2012;21(2):167–173. doi: 10.4104/pcrj.2011.00103
  39. Trofimov VI, Baranov DZ. Clinical and functional peculiarities at patients with bronchial asthma, chronic obstructive pulmonary disease and overlap of asthma-chronic obstructive pulmonary disease. Nefrologiya. 2020;24(4):80–86. EDN: HBKWSH doi: 10.36485/1561-6274-2020-24-4-80-86
  40. Mansur AH, Srivastava S, Sahal A. Disconnect of type 2 biomarkers in severe asthma; dominated by FeNO as a predictor of exacerbations and periostin as predictor of reduced lung function. Respir Med. 2018;143:31–38. doi: 10.1016/j.rmed.2018.08.005
  41. Takahashi K, Meguro K, Kawashima H, et al. Serum periostin levels serve as a biomarker for both eosinophilic airway inflammation and fixed airflow limitation in well-controlled asthmatics. J Asthma. 2019;56(3):236–243. doi: 10.1080/02770903.2018.1455855
  42. Matsumoto H. Roles of periostin in asthma. Adv Exp Med Biol. 2019;1132:145–159. doi: 10.1007/978-981-13-6657-4_15
  43. Johansson MW, Annis DS, Mosher DF. α(M)β(2) integrin-mediated adhesion and motility of IL-5-stimulated eosinophils on periostin. Am J Respir Cell Mol Biol. 2013;48(4):503–510. doi: 10.1165/rcmb.2012-0150OC
  44. Nejman-Gryz P, Górska K, Paplińska-Goryca M, et al. Periostin and thymic stromal lymphopoietin – potential crosstalk in obstructive airway diseases. J Clin Med. 2020;9(11):3667. doi: 10.3390/jcm9113667
  45. Park HY, Lee H, Koh W-J, et al. Association of blood eosinophils and plasma periostin with FEV1 response after 3-month inhaled corticosteroid and long-acting beta2-agonist treatment in stable COPD patients. Int J Chron Obstruct Pulmol Dis. 2015;11:23–30. doi: 10.2147/COPD.S94797
  46. Carpaij OA, Muntinghe FOW, Wagenaar MB, et al. Serum periostin does not reflect type 2-driven inflammation in COPD. Respir Res. 2018;19(1):112. doi: 10.1186/s12931-018-0818-8
  47. Morra L, Rechsteiner M, Casagrande S, et al. Characterization of periostin isoform pattern in non-small cell lung cancer. Lung Cancer. 2012;76(2):183–190. doi: 10.1016/j.lungcan.2011.10.013

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Indicators of the cellular composition of induced sputum in the patients with asthma and chronic obstructive pulmonary disease: lymphocytes (a), neutrophils (b), macrophages (c), eosinophils (d). COPD — chronic obstructive pulmonary disease

下载 (292KB)
索引源数据
3. Fig. 2. Indicators of periostitis in serum in the patients with asthma and chronic obstructive pulmonary disease and the control group. COPD — chronic obstructive pulmonary disease

下载 (79KB)
索引源数据

版权所有 © Eco-Vector, 2024

许可 URL: https://eco-vector.com/for_authors.php#07
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 71733 от 08.12.2017.


##common.cookie##